Get notified when JUNS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Management and auditors have expressed substantial doubt about the company's ability to continue as a going concern.
- Nasdaq Delisting Risk (new) — The company has received multiple Nasdaq non-compliance notices and may be delisted if it fails to regain compliance.
- Immediate Dilution (new) — New investors will suffer immediate dilution of $3.73 per share, representing 57.4% of the offering price.
Jupiter Neurosciences prices $2.0M primary offering at $6.50/share; net proceeds $1.7M
Filed August 24, 2026 · ~1 min read
Key Changes
-
high
Jupiter Neurosciences is offering 307,692 shares at $6.50 per share, with expected proceeds of $2.0M gross and $1.7M net for the company.
The Offering verify on EDGAR → -
medium
The company expects net proceeds of approximately $1.74 million, to be used for working capital and general corporate purposes with broad management discretion.
Use of Proceeds verify on EDGAR → -
high
Investors in this offering will experience immediate dilution of $3.73 per share, with pro forma as adjusted net tangible book value of $2.77 per share after the offering.
Dilution verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WLTH 10-Q) is open in full — no account needed.
Partner
Trade JUNS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify